Publications
5674 Results
- Journal / Conference
- JCO Oncology Practice Mar;16(3):125-127
- Year
- 2020
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID32074016
What Keeps Patients Out of Clinical Trials? [Editorial]
- Journal / Conference
- Hematologist [Clinical Trials Corner] Sept 1 Vol 17, Issue 5
- Year
- 2020
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (SWOG Intergroup S1826)
- Journal / Conference
- American Journal of Clinical Oncology Mar;43(3):173-179
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID31985516
- PMC
- PMC7280743
- Study Number(s)
- CTSU/R0848
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial
- Journal / Conference
- Supportive Care in Cancer Sep 15. doi: 10.1007/s00520-020-05748-8. Online ahead of print
- Year
- 2020
- Research Committee(s)
- Breast
- PMID
- PMID32929540
- Study Number(s)
- S0307
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
- Journal / Conference
- Journal of Clinical Oncology Apr 10;38(11):1126-1137
- Year
- 2020
- Research Committee(s)
- Myeloma
- PMID
- PMID31652094
- PMC
- PMC7145586
- Study Number(s)
- CTSU/E3A06
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- Journal / Conference
- Blood Cancer Journal Feb 13;10(2):17
- Year
- 2020
- Research Committee(s)
- Myeloma
- PMID
- PMID32054831
- PMC
- PMC7018731
- Study Number(s)
- S0777
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
- Journal / Conference
- Journal of Clinical Oncology Feb 20;38(6):567-575
- Year
- 2020
- Research Committee(s)
- Melanoma
- PMID
- PMID31880964
- PMC
- PMC7030886
- Study Number(s)
- CTSU/E1609
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- Journal / Conference
- American Society for Preventative Oncology annual meeting (March 22-24, 2020, Tucson, AZ), poster
- Year
- 2020
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Serological evidence of infections is associated with extent and intensity of intra-prostatic inflammation in men without prostate cancer or indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- International Symposium on Amyloidosis (virtual September 14-18, 2020, Tarragona, Spain), oral, #OP35
- Year
- 2020
- Research Committee(s)
- Myeloma
- Study Number(s)
- S1702
A Phase II Study of Isatuximab (Sar650984) (Nsc-795145) for Patients with Previously Treated Al Amyloidosis (SWOG S1702; NCT#03499808)
- Journal / Conference
- Cancer Epidemiology Biomarkers & Prevention Dec;29(12):2735-2739
- Year
- 2020
- Research Committee(s)
- Cancer Control, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID32967863
- PMC
- PMC8195110
- Study Number(s)
- S0000, SWOG-9217